Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

5.3%

1 terminated/withdrawn out of 19 trials

Success Rate

92.9%

+6.4% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

23%

3 of 13 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

Phase 1
14(77.8%)
Phase 2
4(22.2%)
18Total
Phase 1(14)
Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (19)

Showing 19 of 19 trials
NCT03673748Phase 2Recruiting

Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells

Role: lead

NCT03884569Not Yet Recruiting

Cultivated Limbal Epithelial Transplantation (CLET) for Limbal Stem Cell Deficiency (LSCD)

Role: collaborator

NCT01860417Phase 1Completed

Treatment of Degenerative Disc Disease With Allogenic Mesenchymal Stem Cells (MSV)

Role: lead

NCT04361942Phase 2Completed

Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stem Cells

Role: lead

NCT02566655Phase 1Completed

Clinical Trial of Intravenous Infusion of Fucosylated Bone Marrow Mesenchyme Cells in Patients With Osteoporosis

Role: lead

NCT01513694Phase 1Completed

Clinical Trial Based on the Use of Mesenchymal Stem Cells From Autologous Bone Marrow in Patients With Lumbar Intervertebral Degenerative Disc Disease

Role: lead

NCT01389661Phase 1Completed

Treatment Of Maxillary Bone Cysts With Autologous Bone Mesenchymal Stem Cells (MSV-H)

Role: lead

NCT02280135Phase 1Completed

Clinical Trial of Intravitreal Injection of Autologous Bone Marrow Stem Cells in Patients With Retinitis Pigmentosa

Role: lead

NCT02045745Phase 1Unknown

Clinical Trial Phase I/II Prospective, Open Nonrandomized for Treatmen of Postoperative Air Leak After Lung Resection in High Risk Patients Through the Administration of Mesenchymal Autologous Cells

Role: lead

NCT02104440Phase 2Completed

Clinical Trial In The Treatment Of Allogeneic Post-Transplant Cytopenias With Sequential Infusion Of Allogeneic Mesenchymal Cells Expanded In Vitro

Role: lead

NCT01824381Phase 1Completed

Use of the Amniotic Membrane in Large Wound Epithelialization

Role: lead

NCT01700920Phase 2Completed

PHASE II CLINICAL TRIAL Prospective, Open, Nonrandomized Treatment of Osteonecrosis of the Femoral Head by the Administration of Autologous Mesenchymal Stem Cells

Role: lead

NCT01824368Phase 1Completed

Extracorporeal Photopheresis in Liver Transplantation. Phase II Clinical Trial in Safety and Efficacy in Patients With Gradual Decrease of Immunosuppression.

Role: lead

NCT02286011Phase 1Unknown

Intramuscular Infusion of Autologous Bone Marrow Stem Cells in Patients With Amyotrophic Lateral Sclerosis

Role: lead

NCT02566681Phase 1Unknown

Clinical Trial of Use of Autologous Bone Marrow Stem Cells Seeded on Porous Tricalcium Phosphate Matrix and Demineralized Bone Matrix in Patients With Osteonecrosis

Role: lead

NCT01586312Phase 1Completed

Treatment of Knee Osteoarthritis With Allogenic Mesenchymal Stem Cells

Role: lead

NCT02440074Phase 1Withdrawn

Lumbar Degenerative Disc Disease Treatment With Bone Marrow Autologous Mesenchymal Stem Cells (MSV)

Role: lead

NCT01183728Phase 1Completed

Treatment of Knee Osteoarthritis With Autologous Mesenchymal Stem Cells

Role: lead

NCT01562002Phase 1Completed

Safety Study of Stem Cell Transplant to Treat Limbus Insufficiency Syndrome

Role: collaborator

All 19 trials loaded